Clinical Trial Update: Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating switching virologically suppressed people living with HIV on opioid agonist therapy from their current ART to the dolutegrav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Opioid Use Disorder

Drugs mentioned

• Dolutegravir/Lamivudine (dolutegravir/lamivudine)

Snippet

Sponsor: Saskatchewan Health Authority - Regina Area | Conditions: HIV-1-infection, Opioid Use Disorder | Phase 4 | Status: NOT_YET_RECRUITING